We and our affiliates and vendors use cookies and similar technologies to operate our sites, recognize visitors to our sites, provide secure log-in, collect statistics to optimize site functionality, and deliver content tailored to your interests. Click Accept All to accept all cookies and go directly to the site, click Reject All to reject all but cookies strictly necessary to the functioning of this site (required cookies), or click on Manage Settings to see detailed descriptions of the types of cookies and choose whether to accept certain cookies while on the site.
Order Status
visit thermofisher.com
AllType FASTplex v2: Our HLA Laboratory Experience ASHI 2021 Symposium
Having trouble viewing this video? Click here.
Dr. Mostafa’s laboratory wanted to implement next-generation sequencing (NGS) to resolve HLA alleles in transplant patients. They evaluated ~640 HLA alleles with the One Lambda™ AllType™ FASTplex™ v2 NGS Assay, and results obtained were ≥99.8% concordant with those obtained using their usual method. Results obtained with the recommended AllType FASTplex NGS v2 protocol and an alternative protocol AllType FASTplex NGS v2 that omitted DNA purification were 100% concordant, and the laboratory was able to reduce its turnaround time by one full working day.
Share This Page
Speaker:
Ahmed Mostafa, MD, PhD
St. Paul’s Hospital, Saskatoon, Canada
Recorded:
Sep 28, 2021
Series: ASHI 2021 Symposium | Adapting Laboratory Diagnostics to a Changing Landscape
Videos In This Series
Filling in the gaps: A Single-Center Experience with ExPlex
© 2025 Thermo Fisher Scientific Inc. All rights reserved.